AI Medicine: Big Pharma Investing Billions, But Success Is Debatable
THE SO WHAT
Billions into AI drug discovery with “debatable” success means timelines and validation, not enthusiasm, are the choke points. Biopharma leaders should narrow AI bets to programs with clear assay feedback loops and regulatory pathways, and kill or pause the rest rather than spreading capital thin across hype.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechArgonne Researchers Couple Spin Waves With Superconducting Circuits
Coupling spin waves with superconducting circuits is another step toward more practical quantum information systems. Deep-tech operators should clock this as long-horizon R&D that could reshape secure comms and specialized compute, but not something to re-architect around this cycle.
Deep & Emerging TechCompact Analog Signal Generators for Fast RF Testing
Shrinking RF test gear into compact analog generators is about throughput and bench density—faster gain, distortion, and blocker tests with less footprint. For hardware teams, this is a reminder that test infrastructure is a lever on cycle time, not just a cost center.
Deep & Emerging TechIsraeli Firms Placed Spyware at Al Jazeera via Ads, Report Says
Using ad networks as a delivery vector for spyware shows how deeply the ad-tech stack has become part of the security threat surface. Any organization relying on third-party ads or trackers should be treating them as untrusted code and tightening browser, network, and endpoint controls accordingly.
Deep & Emerging TechTSMC says it plans to build an additional 3nm fab in Tainan, Taiwan, set for production in H1 2028, alongside its 3nm capacity in Arizona and Japan's Kumamoto
TSMC adding another 3nm fab in Tainan for H1 2028, on top of Arizona and Kumamoto, confirms that advanced-node capacity will keep expanding—but on multi-year timelines. If your roadmap depends on bleeding-edge silicon, align product launches and AI infra plans with this 2028+ capacity curve, not next quarter’s hype.